Natural Product Drug Discovery: Are Hidden Compounds Messing with Your Results?
"Tannins and chlorophylls could be skewing your zebrafish assay results. Learn how to spot and handle these interferences for more reliable natural product research."
Natural products offer a rich source of compounds for drug development. However, their complex composition can create challenges in identifying active molecules using high-throughput screens (HTS). Many assays rely on colorimetric or luminescence-based measurements, which can be disrupted by the presence of tannins and chlorophylls, potentially leading to false positives or negatives.
Zebrafish assays offer an alternative approach to bioprospecting naturally occurring bioactive compounds, yet the interference potential of tannins and chlorophylls in these assays has remained unclear. A recent study investigates the extent to which these compounds can affect the outcomes of zebrafish phenotypic assays, and offers insights into optimizing your research.
This article explores the findings of that study, focusing on how tannins and chlorophylls can interfere with the efficacy of known small-molecule inhibitors in zebrafish embryos. By understanding these interferences, researchers can develop more reliable screening methods for identifying promising drug candidates from natural sources.
A High-Risk, High-Cost Pipeline
Drug discovery is widely described in the scientific literature as a costly, time-consuming enterprise in which the majority of candidate compounds fail before reaching patients. Much of the financial and timeline risk sits in the later stages, where safety failures are most expensive. These pressures have led regulators and funders to encourage earlier and more predictive assessment of efficacy and toxicity. Because sources differ on precise failure rates and costs, specific figures are best treated as approximate.
From In Vitro to In Vivo — and the Zebrafish as a Bridge
Safety evaluation in early drug discovery has traditionally moved through in silico, in vitro, and in vivo studies in sequence, constrained by the small amounts of compound available and the throughput limits of each assay system. In vitro assays are effective at detecting particular tissue-specific toxicity phenotypes, but the pipeline overall faces escalating costs, extended timelines, and failure rates reported at roughly 90%. Against this backdrop, the National Institutes of Health (NIH) and the US Food and Drug Administration (FDA) have issued guidance to reduce animal testing, positioning zebrafish (Danio rerio) as a New Approach Methodology (NAM) that bridges high-throughput in vitro assays and mammalian models. Zebrafish offer genetic tractability, optical transparency, and rapid development, yet current screening platforms still struggle with limited automation and throughput, and with accuracy losses driven by heterogeneity among individual fish.
From Lab Organism to Screening Workhorse
Zebrafish were first established as a model organism in basic biomedical research, valued for traits such as optical transparency and external development. Over time, the fish's genetic tractability expanded its use from developmental biology into disease modeling and chemical screening. More recently, the community has pushed toward standardization, automated platforms, and New Approach Methodology status within regulatory science. The precise chronology of these milestones is not covered consistently across sources, so this timeline is offered as a general sketch rather than a definitive history.
Tannins and Chlorophylls: The Usual Suspects in Assay Interference
Tannins and chlorophylls are common secondary metabolites found in plants. Tannins, known for their protein-binding properties, can interfere with enzymatic assays and radioligand receptor-binding assays. Chlorophylls, with their strong light absorption, can disrupt colorimetric assays. Both have the potential to skew results in high-throughput screens, leading to inaccurate identification of active compounds.
- Tannins: Can bind to proteins, interfering with enzyme and receptor assays.
- Chlorophylls: Absorb light strongly, disrupting colorimetric measurements.
- Both: Can lead to false positives or false negatives in high-throughput screens.
Fresh Reviews: CNS Disease, Genetic Workflows, and Clinic-Bound Compounds
Recent reviews continue to expand zebrafish applications across discovery research. A 2025 review comparing the human and zebrafish central nervous system highlights sex-specific differences and examines behavioral assays for disease modeling and neurotoxicity studies, with particular attention to stroke and Alzheimer's disease (AD). A 2025 overview in BioEssays details the model's workflow, from egg breeding and plating through gene knockout, knockdown, and transgenesis used to study gene function. Independent coverage notes that drug screening in zebrafish now supports target identification, illness modelling, and high-throughput screening of compounds, and that several drugs that recently entered the clinic or clinical trials trace their origins to zebrafish. Together these reviews illustrate a maturing field, though each emphasizes different parts of the pipeline.
Warnings and Setbacks in the Model
Critics of zebrafish-based discovery point to real limitations that temper enthusiasm for the model. Chief among them are translational gaps between fish biology and human physiology, which mean signals in zebrafish do not always hold up in mammals. Technical constraints, including heterogeneity among individual fish and modest automation in many screening platforms, further complicate the reproducibility of results. Because the sources reviewed here do not provide specific, quantified failure cases, this account is necessarily qualitative rather than a catalog of documented failures.
How Zebrafish Stack Up Against Alternative Models
In comparative terms, zebrafish sit between in vitro and rodent models on most measures of throughput, physiological relevance, and cost. Their optical transparency and small size support higher-throughput screens than mammalian in vivo studies, while their genetic tractability brings experimental control that simple cell culture lacks. Yet they are generally considered less physiologically representative of humans than rodents for certain endpoints, and assay heterogeneity remains a concern. The sources examined here do not supply a systematic, head-to-head scoring of the models, so these comparisons should be read as broad trends rather than precise rankings.
Key Takeaways and Implications for Researchers
The study revealed that tannins and chlorophylls can indeed interfere with zebrafish phenotypic assays, although the extent of interference depends on the specific target and assay. For example, tannin-enriched fractions (TEF) partially masked the antiangiogenic effect of sunitinib malate, while chlorophyll-enriched fractions (CEF) enhanced the activity of γ-secretase inhibitors, leading to toxicity.
Experts Weigh In: A Versatile but Demanding Tool
Expert commentary positions the zebrafish as a well-established model organism whose utility now spans drug discovery, from phenotypic screens through safety testing. Patton, Zon, and Langenau, in a widely cited 2021 review, discuss key recent successes in screening, disease modelling, and toxicity assays. Toxicology-focused analyses explain the rationale for zebrafish in drug discovery toxicology, describe life stages as they relate to laboratory practice, and use case studies to show how the fish can expose mechanisms of toxicity and predict toxic responses; they also caution that the larval and adult safety screens developed over the past decade carry both benefits and pitfalls. Together, expert sources agree the model is valuable but emphasize that its outputs depend heavily on sound experimental design.
Quantifying the Trajectory: Publications and Market Projections
A bibliometric and methodological analysis of 20,291 publications from 2014 to 2024 characterizes the zebrafish as an indispensable model in toxicological research, bridging environmental monitoring, disease modeling, and preclinical drug screening. Industry analysis separately projects significant growth in the global Zebrafish for Biotech market, driven by rising demand for zebrafish models in drug discovery and development, citing the fish's genetic similarity to humans and its amenability to genetic manipulation for preclinical studies. The two sources converge on a growing and increasingly professionalized field. The market figures are forward-looking projections, however, and should be treated as estimates rather than guarantees.
The Systemic Pressures Shaping the Field
The rise of zebrafish in discovery research sits within a larger push across the drug-development landscape for faster, cheaper, and more humane ways to predict how compounds will behave in humans. Regulators, funders, and developers are all under pressure to reduce animal use, cut attrition, and contain costs, which favors approaches that promise earlier and more scalable safety data. At the same time, the infrastructure needed — automation, standardized husbandry, data pipelines, and skilled personnel — is significant, and adoption has been uneven across institutions and regions. This account is necessarily general, as the sources reviewed here do not quantify these systemic forces.
Researchers, Animals, and Patients at the Center
Behind the technical advances are real human stakes: researchers who need dependable models, laboratory staff who work with the animals, and patients waiting for therapies that may never reach the clinic. Decisions about which model systems to trust therefore carry consequences well beyond the bench. Zebrafish-based approaches promise to reduce the number of mammals used in discovery, which has both ethical and practical appeal, yet the transition changes workflows and the expertise required of scientists. The sources reviewed here do not provide personal accounts or patient-outcome data, so this discussion remains a general observation rather than a documented case study.
These findings underscore the importance of carefully optimizing assays and assessing the interference potential of tannins and chlorophylls before conducting screening assays. Researchers should consider the following:
By understanding and addressing these potential interferences, researchers can improve the reliability of zebrafish assays and increase their chances of identifying promising drug candidates from natural products. While this article showcases this with natural extracts isolated from Camellia sinensis, you can also assess this on different plants and species with similar parameters.